Other languages 180 Life Sciences Corp.

Equities

KBLM

US68236V3024

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
2.13 ^USD	-7.79%		+36.54%	-47.49%

May. 15	180 Life Sciences Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 09	180 Life Sciences Corp. Announces Management Changes	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

180 Life Sciences Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15
180 Life Sciences Corp. Announces Management Changes	May. 09
180 Life Sciences Corp. Announces Chief Executive Officer Changes	May. 09
180 Life Sciences Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25
180 Life Sciences Corp. Announces Board Changes	Mar. 11
180 Life Sciences Corp. Appoints Blair Jordan as A Member of the Board of Directors	Feb. 29
180 Life Sciences to Conduct 1-For-19 Reverse Stock Split	Feb. 26
180 Life Sciences Corp. Announces Board Resignations	Dec. 21
180 Life Sciences Corp. Announces Resignation of Donald A. Mcgovern, as Member of the Board of Directors	Dec. 20
180 Life Sciences Hires Financial Adviser to Help Explore Strategic Alternatives	Dec. 04
180 Life Sciences Engages Financial Advisor to Explore Strategic Alternatives	Dec. 03
180 Life Sciences Announces Review of Strategic Alternatives	Nov. 28
180 Life Sciences Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09
180 Life Sciences Corp. Receives Formal Written Scientific Response from the United Kingdom's Medicines and Healthcare Products Regulatory Agency	23-10-18
180 Life Sciences Corp. and Oxford University Innovation Limited Enter into a Termination Letter, Formally Terminate the License	23-09-28
180 Life Sciences Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-15
Top Premarket Gainers	23-08-09
180 Life Sciences Announces an Agreement for A Clinical Pharmacology Study Testing A New Formulation of Cbd for Enhanced Oral Uptake	23-08-07
180 Life Sciences Corp. Provides Update on Regulatory Approval Process in the UK and US for Dupuytren's Disease Treatment	23-08-03
180 Life Sciences Corp. Announces the Filing of A Provisional Patent Describing the Combination of CBD with GLP-1 Agonists to Suppress Appetite	23-07-31

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages 180 Life Sciences Corp.

Equities

KBLM

US68236V3024

Other languages

Filters